source
- FDA places partial hold on Bright Minds' seizure trial over mouse toxicity concernsThe FDA issued a partial clinical hold on Bright Minds Biosciences' planned phase 2 trial of BMB-101 in patients with developmental and epileptic encephalopathies. The hold was triggered by precli…
- Top pharma firms line up for Summit Therapeutics' ivonescimab after strong China Phase 3 dataSeveral major biopharma companies, including AstraZeneca, Pfizer and Revolution Medicines, are expressing strong interest in Summit Therapeutics' Akeso-partnered bispecific antibody ivonescimab. Th…